EBV阳性弥漫大B细胞淋巴瘤的诊疗进展  

Advances in diagnosis and treatment in Epstein-Barr virus-positive diffuse large B-cell lymphoma

作　　者：赵晨星 闫子勋[2] 胡建达[1] ZHAO Chenxing;YAN Zixun;HU Jianda

机构地区：[1]福建医科大学附属协和医院血液内科,福州350001 [2]上海交通大学医学院附属瑞金医院血液内科

出　　处：《临床血液学杂志》2020年第5期654-658,共5页Journal of Clinical Hematology

基　　金：国家自然科学基金(No:81870135);福建省财政专项经费(No:2016B041、2019CZ003);福建省高校产学合作项目(No:2017Y4005);福建医科大学启航基金项目(No:2017XQ2030)。

摘　　要：Epstein-Barr病毒(Epstein-Barr virus,EBV)是一种十分常见的γ-1型疱疹病毒,感染率多达90%[1]。EBV具有强大的诱导淋巴细胞恶性转化的能力,其致癌作用首次在Burkitt淋巴瘤细胞系中得以明确,随后在其他淋巴瘤中也相继报道,包括弥漫大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)及其他淋巴瘤亚型[2-3]。Epstein-Barr virus(EBV)is a very common gamma-1 herpes virus with an infection rate of 90%.EBV is the first virus reported to have a clear carcinogenic effect,and its carcinogenicity was further confirmed in diffuse large B cell lymphoma(DLBCL)and other lymphoma subtypes.The 2016 World Health Organization(WHO)classified EBV-related DLBCL as a new subtype of DLBCL(EBV^+DLBCL,NOS).The proportion of EBV^+DLBCL is higher in China than in Western countries and associated with poor prognosis.EBER in situ hybridization detection in tumors is considered as the gold standard diagnosis for EBV^+DLBCL.Besides,EBV DNA copy number,EBV serum serological profile and molecular signatures can be used as important auxiliary detection methods.At present,EBV^+DLBCL mainly treated with chemotherapy still could not achieve treatment benefits.With the increased studies of EBV^+DLBCL targeted therapy,the more therapy strategies for EBV^+DLBCL are considered.In this review,we discuss the advance in the diagnosis,monitoring,and treatment of EBV^+DLBCL,to provide evidence for clinicians in the diagnosis and clinical target therapy for EBV^+DLBCL.

关 键 词：EBV病毒 弥漫大B细胞淋巴瘤 生物学标志物 靶向治疗 

分 类 号：R733.4[医药卫生—肿瘤]